diaDexus

About:

diaDexus is a biotechnology company focused on the development and commercialization of diagnostic products with high clinical value.

Website: http://www.diadexus.com

Top Investors: Scale Venture Partners, Rho Capital Partners, GSK, Oxford Finance LLC, Baker Brothers Advisors LLC

Description:

diaDexus is a privately held biotechnology company that is focused on the discovery, development and commercialization of novel, patent protected diagnostic products with high clinical value. The company's lead product, the PLAC Test, measures Lp-PLA2 (lipoprotein-associated phospholipase A2) a vascular-specific inflammatory enzyme implicated in the formation of rupture-prone plaque. It is plaque rupture and thrombosis, not stenosis, that cause the majority of cardiovascular events. The PLAC Test is the only blood test cleared by the FDA as an aid in assessing risk for coronary heart disease, and ischemic stroke associated with atherosclerosis.

Total Funding Amount:

$171M

Estimated Revenue Range:

$10M to $50M

Headquarters Location:

South San Francisco, California, United States

Founded Date:

1997-01-01

Contact Email:

support(AT)diazyme.com

Founders:

Number of Employees:

51-100

Last Funding Date:

2014-08-18

IPO Status:

Public

Industries:

© 2025 bioDAO.ai